J&J: endpoints met in UC

(CercleFinance.com) - Johnson & Johnson announced on Friday that its Phase III trial of Tremfya in the treatment of ulcerative colitis had met all its primary and secondary endpoints.


The study showed that after 12 weeks, the subcutaneous drug had enabled 27.6% of treated patients to go into remission, compared with 6.5% in the placebo group.

In addition, 65.6% of participants showed a response to treatment, versus 34.5% for placebo, with an improvement in endoscopy in 37.3%, compared with 12.9% for placebo.

Developed by Janssen, J&J's biopharmaceutical subsidiary, Tremfya is a monoclonal antibody already approved for psoriatic arthritis and plaque psoriasis.


Copyright (c) 2025 CercleFinance.com. All rights reserved.